Active, not recruitingPhase 2NCT04803877
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Intervention
- Regorafenib 40 MG(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2021 – 2026
Study locations (8)
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- University of Miami, Miami, Florida, United States
- Johns Hopkins, Baltimore, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Cincinnati Children's, Cincinnati, Ohio, United States
- Oregon Health and Sciences University, Portland, Oregon, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04803877 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.
- RECRUITINGPHASE1, PHASE2NCT06892678DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaMontefiore Medical Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05660408RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid TumorsUniversity of Florida